[1] |
LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian.
Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
|
[2] |
XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling.
Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
|
[3] |
YUAN Zhen, CHEN Bilian.
Review of bleeding events in clinical studies of clopidogrel
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 341-349.
|
[4] |
XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang.
Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
|
[5] |
PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie.
Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
|
[6] |
YANG Rui, LIU Hui, CHEN Zeheng, QI Tingting,ZHANG Zanling, QU Qiang.
Clinical pharmacists use CYP2C19 genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 938-943.
|
[7] |
WANG Weiyu, YU Hao.
Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
|
[8] |
ZHANG Xia, KE Yong-sheng.
Clinical research of new type P2Y12 Receptor inhibitor ticagrelor
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 459-464.
|
[9] |
YAN Fu-qin, FAN Zhen.
Improve and correct the Clinical Guide to Platelet Aggregation Inhibitors for no-cardiac surgery
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1352-1355.
|
[10] |
YANG Yong-ge, ZHANG Mei, JIANG Nan, SONG Li-xue, XU Xue-ting, DI Xiao-hui, XU Lin, XU Juan,ZHAO Gang-tao.
Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 38-43.
|
[11] |
YUN Wen-bo1, JIANG Peng-li1, WU Jing1, SUN He1,2.
Bleeding risk is higher when warfarin used alone compared to the associated use of aspirin with clopidogrel
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1251-1259.
|
[12] |
LIAO Chun-xing, PAN Qiao-ling, YANG Jian-quan, ZHU De-xia, ZHANG Jun.
Clopidogrel prevent late malfunction in tunneled cuffed hemodialysis catheters
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 687-690.
|
[13] |
QIAN Jian, XU Jian.
Effects of simvastatin combining clopidogrel on high-sensitivity C-reactive protein and blood lipids in patients with acute coronary syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 206-209.
|
[14] |
HE Chun-hui, HU Qin , ZOU Jian-jun, CHEN Shao-liang, FAN Hong-wei, XIE Hong-guang, ZHU Yu-bing.
Study on genetic factors of clopidogrel resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1288-1293.
|
[15] |
CHEN Bi-lian, XIE Qin-zhi, LI Qing.
Clinical observation of clopidogrel resistance and clinical outcomes on patients with acute coronary syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(3): 328-332.
|